Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 Sep;89(3):407–413. doi: 10.1111/j.1365-2249.1992.tb06971.x

Ivermectin-facilitated immunity in onchocerciasis. Reversal of lymphocytopenia, cellular anergy and deficient cytokine production after single treatment.

P T Soboslay 1, C M Dreweck 1, W H Hoffmann 1, C G Lüder 1, C Heuschkel 1, H Görgen 1, M Banla 1, H Schulz-Key 1
PMCID: PMC1554489  PMID: 1516257

Abstract

A longitudinal investigation has been conducted into the cell-mediated immune responses of onchocerciasis patients after a single-dose treatment with ivermectin. Untreated patients tested for delayed cutaneous hypersensitivity (DCH) to seven recall antigens showed lower responses than infection-free control individuals (P less than 0.01), but 6 and 14 months after treatment DCH reactions increased to similar levels to those seen in the controls. The in vitro cellular reactivity to Onchocerca volvulus-derived antigen (OvAg) was reduced in untreated patients as compared with controls, and the lymphocyte blastogenic responses to OvAg and streptolysin-O clearly improved up to 14 months after treatment. Peripheral blood mononuclear cells (PBMC) from untreated patients produced IL-1 beta, tumour necrosis factor-alpha (TNF-alpha) and IL-6 in response to mitogenic stimulation with phytohaemagglutinin (PHA), only low levels of IL-1 beta, IL-2 and TNF-alpha in response to OvAg, but higher amounts of IL-4 and interferon-gamma (IFN-gamma) in response to OvAg than control individuals. After ivermectin treatment, the OvAg-induced production of IL-1 beta and TNF-alpha increased significantly 1 and 14 months after treatment. The PHA-induced production of IL-2 and IL-4 increased 1 month after treatment and remained significantly elevated until 14 months after treatment, whereas the OvAg-specific secretion of IL-2, IL-4 and IFN-gamma did not change after ivermectin treatment. Flow cytometric analysis of lymphocyte-subsets in the peripheral blood of untreated patients revealed a relative and absolute (P less than 0.01) diminution of CD4+ cells and a significantly smaller CD4+/CD8+ cell ratio as compared with controls. By 4 weeks after treatment and thereafter, CD4+ T cells increased relatively and absolutely (P less than 0.01); likewise there was an absolute increase in T-helper-inducer cells (CD4+CD45RO+) and a temporarily improved CD4+/CD8+ cell ratio (P = 0.001). The expression of the low-affinity receptor for IgE (CD23) on total lymphocytes decreased from 14% to 7% by 14 months after treatment. The CD8+ cells and CD3+TCR gamma delta + cells were higher in patients than in controls and both remained elevated until 14 months after treatment. These results suggest a distinctly improved cellular immunity in human onchocerciasis that was facilitated by ivermectin therapy.

Full text

PDF
407

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akbar A. N., Terry L., Timms A., Beverley P. C., Janossy G. Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. J Immunol. 1988 Apr 1;140(7):2171–2178. [PubMed] [Google Scholar]
  2. Aziz M. A., Diallo S., Diop I. M., Lariviere M., Porta M. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet. 1982 Jul 24;2(8291):171–173. doi: 10.1016/s0140-6736(82)91026-1. [DOI] [PubMed] [Google Scholar]
  3. Born W. K., O'Brien R. L., Modlin R. L. Antigen specificity of gamma delta T lymphocytes. FASEB J. 1991 Sep;5(12):2699–2705. doi: 10.1096/fasebj.5.12.1717333. [DOI] [PubMed] [Google Scholar]
  4. Darge K., Lucius R., Monson M. H., Behrendsen J., Büttner D. W. Immunohistological and electron microscopic studies of microfilariae in skin and lymph nodes from onchocerciasis patients after ivermectin treatment. Trop Med Parasitol. 1991 Dec;42(4):361–367. [PubMed] [Google Scholar]
  5. Delespesse G., Suter U., Mossalayi D., Bettler B., Sarfati M., Hofstetter H., Kilcherr E., Debre P., Dalloul A. Expression, structure, and function of the CD23 antigen. Adv Immunol. 1991;49:149–191. doi: 10.1016/s0065-2776(08)60776-2. [DOI] [PubMed] [Google Scholar]
  6. Finkelman F. D., Pearce E. J., Urban J. F., Jr, Sher A. Regulation and biological function of helminth-induced cytokine responses. Immunol Today. 1991 Mar;12(3):A62–A66. doi: 10.1016/S0167-5699(05)80018-0. [DOI] [PubMed] [Google Scholar]
  7. Freedman D. O., Lujan-Trangay A., Steel C., Gonzalez-Peralta C., Nutman T. B. Immunoregulation in onchocerciasis. Functional and phenotypic abnormalities of lymphocyte subsets and changes with therapy. J Clin Invest. 1991 Jul;88(1):231–238. doi: 10.1172/JCI115282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gallin M., Edmonds K., Ellner J. J., Erttmann K. D., White A. T., Newland H. S., Taylor H. R., Greene B. M. Cell-mediated immune responses in human infection with Onchocerca volvulus. J Immunol. 1988 Mar 15;140(6):1999–2007. [PubMed] [Google Scholar]
  9. Goa K. L., McTavish D., Clissold S. P. Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs. 1991 Oct;42(4):640–658. doi: 10.2165/00003495-199142040-00007. [DOI] [PubMed] [Google Scholar]
  10. Greene B. M., Fanning M. M., Ellner J. J. Non-specific suppression of antigen-induced lymphocyte blastogenesis in Onchocerca volvulus infection in man. Clin Exp Immunol. 1983 May;52(2):259–265. [PMC free article] [PubMed] [Google Scholar]
  11. Greene B. M., Gbakima A. A., Albiez E. J., Taylor H. R. Humoral and cellular immune responses to Onchocerca volvulus infection in humans. Rev Infect Dis. 1985 Nov-Dec;7(6):789–795. doi: 10.1093/clinids/7.6.789. [DOI] [PubMed] [Google Scholar]
  12. Janeway C. A., Jr, Jones B., Hayday A. Specificity and function of T cells bearing gamma delta receptors. Immunol Today. 1988 Mar;9(3):73–76. doi: 10.1016/0167-5699(88)91267-4. [DOI] [PubMed] [Google Scholar]
  13. Kilian H. D., Nielsen G. Cell-mediated and humoral immune responses to BCG and rubella vaccinations and to recall antigens in onchocerciasis patients. Trop Med Parasitol. 1989 Dec;40(4):445–453. [PubMed] [Google Scholar]
  14. Lammie P. J., Katz S. P. Immunoregulation in experimental filariasis. II. Responses to parasite and nonparasite antigens in jirds with Brugia pahangi. J Immunol. 1983 Mar;130(3):1386–1389. [PubMed] [Google Scholar]
  15. Leiva L. E., Lammie P. J. Regulation of parasite antigen-induced T cell growth factor activity and proliferative responsiveness in Brugia pahangi-infected jirds. J Immunol. 1989 Feb 15;142(4):1304–1309. [PubMed] [Google Scholar]
  16. Mitchell L. C., Davis L. S., Lipsky P. E. Promotion of human T lymphocyte proliferation by IL-4. J Immunol. 1989 Mar 1;142(5):1548–1557. [PubMed] [Google Scholar]
  17. Mosmann T. R., Cherwinski H., Bond M. W., Giedlin M. A., Coffman R. L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986 Apr 1;136(7):2348–2357. [PubMed] [Google Scholar]
  18. Nutman T. B., Kumaraswami V., Ottesen E. A. Parasite-specific anergy in human filariasis. Insights after analysis of parasite antigen-driven lymphokine production. J Clin Invest. 1987 May;79(5):1516–1523. doi: 10.1172/JCI112982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pacqué M., Muñoz B., Greene B. M., Taylor H. R. Community-based treatment of onchocerciasis with ivermectin: safety, efficacy, and acceptability of yearly treatment. J Infect Dis. 1991 Feb;163(2):381–385. doi: 10.1093/infdis/163.2.381. [DOI] [PubMed] [Google Scholar]
  20. Piessens W. F., Partono F., Hoffman S. L., Ratiwayanto S., Piessens P. W., Palmieri J. R., Koiman I., Dennis D. T., Carney W. P. Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. N Engl J Med. 1982 Jul 15;307(3):144–148. doi: 10.1056/NEJM198207153070302. [DOI] [PubMed] [Google Scholar]
  21. Piessens W. F., Ratiwayanto S., Piessens P. W., Tuti S., McGreevy P. B., Darwis F., Palmieri J. R., Koiman I., Dennis D. T. Effect of treatment with diethylcarbamazine on immune responses to filarial antigens in patients infected with Brugia malayi. Acta Trop. 1981 Sep;38(3):227–234. [PubMed] [Google Scholar]
  22. Prost A., Schlumberger M., Fayet M. T. Response to tetanus immunization in onchocerciasis patients. Ann Trop Med Parasitol. 1983 Feb;77(1):83–85. doi: 10.1080/00034983.1983.11811675. [DOI] [PubMed] [Google Scholar]
  23. Salgame P., Abrams J. S., Clayberger C., Goldstein H., Convit J., Modlin R. L., Bloom B. R. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science. 1991 Oct 11;254(5029):279–282. doi: 10.1126/science.254.5029.279. [DOI] [PubMed] [Google Scholar]
  24. Salmon M., Kitas G. D., Bacon P. A. Production of lymphokine mRNA by CD45R+ and CD45R- helper T cells from human peripheral blood and by human CD4+ T cell clones. J Immunol. 1989 Aug 1;143(3):907–912. [PubMed] [Google Scholar]
  25. Schulz-Key H., Albiez E. J., Büttner D. W. Isolation of living adult Onchocerca volvulus from nodules. Tropenmed Parasitol. 1977 Dec;28(4):428–430. [PubMed] [Google Scholar]
  26. Soboslay P. T., Dreweck C. M., Taylor H. R., Brotman B., Wenk P., Greene B. M. Experimental onchocerciasis in chimpanzees. Cell-mediated immune responses, and production and effects of IL-1 and IL-2 with Onchocerca volvulus infection. J Immunol. 1991 Jul 1;147(1):346–353. [PubMed] [Google Scholar]
  27. Steel C., Lujan-Trangay A., Gonzalez-Peralta C., Zea-Flores G., Nutman T. B. Immunologic responses to repeated ivermectin treatment in patients with onchocerciasis. J Infect Dis. 1991 Sep;164(3):581–587. doi: 10.1093/infdis/164.3.581. [DOI] [PubMed] [Google Scholar]
  28. Weiss N. Dipetalonema viteae: in vitro blastogenesis of hamster spleen and lymph node cells to phytohemagglutinin and filarial antigens. Exp Parasitol. 1978 Dec;46(2):283–299. doi: 10.1016/0014-4894(78)90142-x. [DOI] [PubMed] [Google Scholar]
  29. White A. T., Newland H. S., Taylor H. R., Erttmann K. D., Keyvan-Larijani E., Nara A., Aziz M. A., D'Anna S. A., Williams P. N., Greene B. M. Controlled trial and dose-finding study of ivermectin for treatment of onchocerciasis. J Infect Dis. 1987 Sep;156(3):463–470. doi: 10.1093/infdis/156.3.463. [DOI] [PubMed] [Google Scholar]
  30. Yamaoka K. A., Tsukidate S., Higaki M., Miyasaka N., Fujita K. Induction of Fc epsilon RII/CD23 on human T cells by excretory and secretory antigen of Dirofilaria immitis. Int Arch Allergy Appl Immunol. 1991;95(1):92–93. doi: 10.1159/000235460. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES